Skip to content

A Study on the Uric Acid-Lowering Effects of Lactobacillus fermentum Supplementation

A Study on the Uric Acid-Lowering Effects of Lactobacillus fermentum Supplementation

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600125986
Enrollment
Unknown
Registered
2026-06-02
Start date
2026-06-03
Completion date
Unknown
Last updated
2026-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperuricemia

Interventions

Lactobacillus fermentum group:Lactobacillus fermentum at a dose of 2 x 10^10 CFU, once daily, one sachet per dose (1g/sachet)

Sponsors

The Second Affiliated Hospital of Xi’an Jiaotong University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Age 18 to 70 years, with a male proportion of no less than 30%. 2. Serum uric acid (SUA) = 480 µmol/L at screening, and SUA = 420 µmol/L at a subsequent test with an interval of at least 24 hours.

Exclusion criteria

Exclusion criteria: 1. Inability to consume oral food or comply with the prescribed intake of the study product; 2. Inability to provide clear and coherent self-reports; 3. Women who are pregnant, lactating, or planning to conceive during the study; 4. History of allergies or known hypersensitivity to the study product ingredients; 5. Diagnosed with gout or presence of tophi; 6. Gastrointestinal surgery within the past 30 days, or antibiotic treatment within the past 30 days (excluding topical or genital medications); 7. Inpatients or individuals with acute gastrointestinal diseases within the past 2 weeks; 8. Severe comorbid diseases of the heart, liver, kidney, or hematopoietic system; psychiatric disorders; patients with diabetes requiring insulin; or BMI > 35 kg/m^2; 9. Regular consumption of probiotic products within the past 30 days (more than 3 times per week), or use of medications affecting serum uric acid within the past 2 weeks (e.g., thiazide/loop diuretics, quinolones, aspirin); 10. Abnormal liver or kidney function indicators; 11. Use of urate-lowering drugs (e.g., Allopurinol, Febuxostat, Benzbromarone) within the past 3 months prior to intervention; 12. High-purine dietary habits (intake of animal viscera, seafood, or thick meat broth > 5 times per week) or habitual alcohol consumption (average daily alcohol intake > 25g); 13. Individuals deemed unsuitable for participation by the investigator; 14. Failure to sign the Informed Consent Form.

Design outcomes

Primary

MeasureTime frame
Serum uric acid;

Secondary

MeasureTime frame
Glucose;Triglycerides;Total cholesterol;HDL-C;LDL-C;Hs-CRP;IL-6;Gut Microbiome;Allantoin;

Countries

China

Contacts

Public ContactLiu Xin, Wang Qian

The Second Affiliated Hospital of Xi'an Jiaotong University

xinliu@xjtu.edu.cn+86 150 0920 2712

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 11, 2026